EDSA Edesa Biotech, Inc. - 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 27, 2026, Edesa Biotech, Inc. (the “Company”) held its 2026 Annual General and
Special Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, shareholders approved an amendment (the “Plan
Amendment”) to the Company’s 2019 Equity Incentive Compensation Plan (the “2019 Plan”) to (i) increase the number
of shares available for issuance thereunder by 750,000 shares and (ii) eliminate the annual per participant option grant limit.

The foregoing description of the Plan Amendment does not purport to be
complete and is qualified in its entirety by reference to the full text of the Plan Amendment, which is filed as Exhibit 10.1 to this
Current Report on Form 8-K and incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, 4,901,921 common shares, or approximately 55% of the outstanding common shares entitled to vote, were represented by proxy or in person. The matters voted on by shareholders at the Annual Meeting and the results of such voting are set forth below.

Proposal No. 1 - Election of the Company’s Directors

Based upon the following votes, the shareholders elected Joan Chypyha,
David Liu, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Charles Olson and Carlo Sistilli to serve as members of the Company’s
board of directors until the annual meeting of shareholders to be held in 2027 or until their successors are duly elected and qualified.

For

Withhold

Broker Non-Votes

Joan Chypyha

2,705,856

48,964

2,147,101

David Liu

2,674,286

80,534

2,147,101

Sean MacDonald

2,674,082

80,738

2,147,101

Patrick Marshall

2,706,023

48,797

2,147,101

Pardeep Nijhawan

2,705,297

49,523

2,147,101

Charles Olson

2,705,959

48,861

2,147,101

Carlo Sistilli

2,673,724

81,096

2,147,101

Proposal No. 2 - Advisory Vote on Executive Compensation

The shareholders approved, on an advisory basis, the executive compensation
of the named executive officers as disclosed in the proxy statement for the Annual Meeting, by the following vote.

For

Against

Abstain

Broker Non-Votes

2,670,075

69,281

15,464

2,147,101

Proposal No. 3 - Approval of Amendment to the 2019 Equity Incentive
Compensation Plan

The shareholders approved an amendment to the Company’s 2019 Plan
to (i) increase the number of shares available for issuance thereunder plan by 750,000 shares and (ii) eliminate the annual per participant
option grant limit.

For

Against

Abstain

Broker Non-Votes

2,613,551

130,589

10,680

2,147,101

Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors
and Independent Registered Public Accounting Firm for the Ensuing Year

The shareholders approved the appointment of MNP LLP as the Company’s
auditors and independent registered public accounting firm for the fiscal year ending September 30, 2026.

For

Withhold

Broker Non-Votes

4,814,478

87,443

N/A

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

10.1*

Amendment No. 5 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

* Management contract or compensatory plan or arrangement.